Detalhe da pesquisa
1.
A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma.
Br J Cancer
; 128(6): 1040-1051, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36624219
2.
Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia.
Ann Oncol
; 34(9): 796-805, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414216
3.
FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma.
Ann Oncol
; 33(1): 99-106, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34687894
4.
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.
Ann Oncol
; 33(2): 204-215, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34710571
5.
Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.
Ann Oncol
; 33(9): 968-980, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35716907
6.
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.
Ann Oncol
; 32(7): 917-925, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33798657
7.
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapyâ.
Ann Oncol
; 31(8): 1075-1082, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32387454
8.
Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis.
Clin Exp Immunol
; 202(3): 335-352, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32734627
9.
Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients.
Ann Oncol
; 30(5): 815-822, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30860590
10.
FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma.
Ann Oncol
; 29(10): 2115-2120, 2018 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30137228
11.
Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.
Ann Oncol
; 28(5): 1130-1136, 2017 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28327969
12.
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab.
Ann Oncol
; 28(2): 368-376, 2017 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27687304
13.
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.
Br J Cancer
; 114(10): 1084-9, 2016 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27124339
14.
Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series.
Intern Med J
; 45(10): 1066-73, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26010858
15.
Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.
Br J Cancer
; 111(2): 292-9, 2014 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24918823
16.
Is chemotherapy still an option in the treatment of melanoma?
Ann Oncol
; 26(11): 2203-4, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26374287
17.
Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma.
Oncoimmunology
; 5(9): e1214788, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27757312